NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q4 2023 Earnings Call Transcript

Justin Hall: Yes, so that’s a really great question, Ed, and it sort of follows on Jeff’s question as well. So, we are not developing in R&D and spending our money on new product development, but what you will see is innovation through partners. And so that’s what you saw with the Avenova Allograft in our partnership with BioStem. So, we entered into that agreement and started selling the Avenova Allograft in Q4, which is incredible innovation, a good lucrative agreement that allows both of us to profit. And then more recently with the Eyenovia agreement. So that’s also bringing a lot of innovation, a very unique differentiated product, and bringing that into our portfolio and rolling it out to our customers. So, you will see some product development and some new product rollouts, but it’s going to be all through partnerships and not through our own R&D.

Edward Woo: Great. Thank you and good luck.

Justin Hall: Thanks, Ed.

Operator: Thank you. This concludes our question-and-answer session. I would now like to turn the call back over to Justin Hall for closing remarks.

Justin Hall: Thank you for joining us today and your interest in NovaBay. We’re excited about our refined strategic vision and the opportunities we face with our established eye care business. We look forward to providing an update during our next quarterly call in May. Thanks again and have a nice day.

Operator: The conference is now concluded. Thank you for your participation. You may now disconnect your lines.